Pentwater Capital Management LP Mirati Therapeutics, Inc. Transaction History
Pentwater Capital Management LP
- $9.58 Billion
- Q1 2024
Shares
1 transactions
Others Institutions Holding MRTX
# of Institutions
19Shares Held
3.57MCall Options Held
0Put Options Held
36.6K-
Sawtooth Solutions, LLC3.14MShares$05.07% of portfolio
-
International Biotechnology Trust PLC London, X0216KShares$03.19% of portfolio
-
Tekla Capital Management LLC65.5KShares$00.09% of portfolio
-
Kellner Capital, LLC New York, NY41.4KShares$04.38% of portfolio
-
Brinker Capital Investments, LLC22.7KShares$00.02% of portfolio
About Mirati Therapeutics, Inc.
- Ticker MRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,609,800
- Description
- Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...